Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
04 Aprile 2022 - 1:00PM
Business Wire
Akili Interactive (“Akili” or the “Company”), a leading digital
medicine company pioneering the development of cognitive treatments
through game-changing technologies, today announced that management
will present at Chardan’s Prescription Digital Therapeutics
Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T.
More information on the event can be found here.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Our approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game
experiences.
On January 26, 2022, Akili entered into a definitive agreement
to become publicly traded via a merger with Social Capital Suvretta
Holdings Corp. I (Nasdaq: DNAA), a special purpose acquisition
company. The transaction is expected to close in mid-2022, subject
to satisfaction of the closing conditions, after which Akili will
be listed on the Nasdaq stock market under the new ticker symbol
“AKLI.” For more information, please visit
www.akiliinteractive.com.
Additional Information and Where to Find It
In connection with the proposed business combination transaction
between Social Capital Suvretta Holdings Corp. I (“SCS”) and Akili,
SCS filed a registration statement on Form S-4 (as amended, the
“Registration Statement”) with the SEC on February 14, 2022, which
includes a preliminary prospectus and proxy statement of SCS,
referred to as a proxy statement/prospectus. The Registration
Statement has not yet become effective. When available, a final
proxy statement/prospectus will be sent to all SCS shareholders.
SCS will also file other documents regarding the proposed
transaction with the SEC. SHAREHOLDERS OF SCS ARE ADVISED TO READ
THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL
OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC
IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
Shareholders will be able to obtain free copies of the Registration
Statement, the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC by SCS (when
available) through the website maintained by the SEC at
http://www.sec.gov.
The documents filed by SCS with the SEC also may be obtained
free of charge at SCS’s website at
https://socialcapitalsuvrettaholdings.com/dnaa or upon written
request to 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV
89052.
Participants in the Solicitation
SCS and Akili and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from SCS’s shareholders in connection with the proposed
transaction. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
transaction between Akili and SCS are contained in the proxy
statement/prospectus. You may obtain free copies of these documents
as described in the preceding paragraph.
No Offer or Solicitation
This communication shall not constitute a solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed transaction. This communication shall
not constitute an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any states or jurisdictions in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act or an
exemption therefrom. This press release may be deemed to be
solicitation material in respect of the proposed transactions
contemplated by the proposed business combination between Akili and
SCS.
Forward-Looking Statements
This communication may contain certain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication, including but not
limited to: (i) the risk that the proposed business combination
transaction may not be completed in a timely manner or at all, (ii)
the failure to satisfy the conditions to the consummation of the
proposed transaction, including the adoption of the Merger
Agreement by the shareholders of SCS and the satisfaction of the
minimum cash condition and (iii) the occurrence of any event,
change or other circumstance that could give rise to the
termination of the Merger Agreement. The foregoing list of factors
is not exhaustive. You should carefully consider the foregoing
factors and the other risks and uncertainties described in the
“Risk Factors” section of SCS’s registration statement on Form S-1
(File No. 333-262706 and 333-257543), SCS’s annual report on Form
10-K for the year ended December 31, 2021 filed with the SEC on
March 24, 2022, the Registration Statement on Form S-4, including
those under “Risk Factors” therein, and other documents filed by
SCS from time to time with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Akili and SCS
assume no obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Neither Akili nor SCS gives any
assurance that either Akili or SCS, or the combined company, will
achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220404005330/en/
Investor Relations:
David Buck Solebury Trout Dbuck@soleburytrout.com
Media:
Julie DiCarlo Akili Interactive julie@akiliinteractive.com
Zara Lockshin Solebury Trout zlockshin@soleburytrout.com
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Social Capital Suvretta ... (NASDAQ:DNAA)
Storico
Da Giu 2023 a Giu 2024